NASDAQ:ME 23andMe (ME) Stock Forecast, Price & News $0.98 -0.10 (-8.97%) (As of 12:39 PM ET) Add Compare Share Share Today's Range$0.98▼$1.0550-Day Range$1.00▼$2.0152-Week Range$0.96▼$3.50Volume1.40 million shsAverage Volume2.33 million shsMarket Capitalization$464.50 millionP/E RatioN/ADividend YieldN/APrice Target$4.92 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media 23andMe MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside386.8% Upside$4.92 Price TargetShort InterestBearish8.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.18Based on 4 Articles This WeekInsider TradingSelling Shares$403,610 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector675th out of 961 stocksPharmaceutical Preparations Industry311th out of 454 stocks 3.5 Analyst's Opinion Consensus Rating23andMe has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.92, 23andMe has a forecasted upside of 386.8% from its current price of $1.01.Amount of Analyst Coverage23andMe has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.31% of the float of 23andMe has been sold short.Short Interest Ratio / Days to Cover23andMe has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in 23andMe has recently increased by 3.40%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend Yield23andMe does not currently pay a dividend.Dividend Growth23andMe does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ME. Previous Next 2.3 News and Social Media Coverage News Sentiment23andMe has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for 23andMe this week, compared to 3 articles on an average week.Search InterestOnly 8 people have searched for ME on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows20 people have added 23andMe to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 23andMe insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $403,610.00 in company stock.Percentage Held by Insiders27.55% of the stock of 23andMe is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.23% of the stock of 23andMe is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of 23andMe is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 23andMe is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio23andMe has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About 23andMe (NASDAQ:ME) Stock23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.Read More ME Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ME Stock News HeadlinesSeptember 26, 2023 | americanbankingnews.com23andMe Holding Co. (NASDAQ:ME) Insider Kathy L. Hibbs Sells 38,548 Shares of StockSeptember 21, 2023 | msn.comReporter under investigation for stealing 2 'alien bodies' from MexicoSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 14, 2023 | msn.com23andMe: Hidden Therapeutics AssetSeptember 14, 2023 | finance.yahoo.com23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness ProgramSeptember 10, 2023 | msn.com23andMe Is Too Far From ProfitabilitySeptember 9, 2023 | theguardian.com‘Something happened, somehow something got mixed up’: the at-home DNA test that changed two families for everSeptember 6, 2023 | forbes.comLemonaid Review 2023: What You Need To KnowSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 2, 2023 | msn.com23andMe expands cancer at-home genetic reportSeptember 2, 2023 | msn.comHas anyone got a CRIgenetics, 23andMe, or Ancestry DNA test done?September 1, 2023 | finance.yahoo.com23andMe receives FDA approval to test for cancer variantsSeptember 1, 2023 | msn.comWall Street Breakfast Podcast: 23andMe Receives New FDA Green LightAugust 31, 2023 | msn.com23andMe rises 17% on FDA clearance to report more genetic variantsAugust 31, 2023 | msn.com23andMe stock rallies more than 23% after genetics company gets OK to report more cancer risksAugust 31, 2023 | finance.yahoo.com23andMe Granted New FDA Clearance to Report Additional BRCA VariantsAugust 31, 2023 | benzinga.comGlobal Direct-To-Consumer (DTC) Genetic Testing Market Size is Set to Forecast $22.3 Billion by 2030 | Genomic ExplorationAugust 25, 2023 | news.yahoo.comLabor Day deals are here: $179 Roomba, Apple sale, Bose headphones, $100 off Apple Watch Ultra, moreAugust 22, 2023 | finance.yahoo.com23andMe: DNA testing kit company needs drug discoveryAugust 19, 2023 | msn.comIdaho murder case DNA issues raise questions about 23AndMe, Ancestry DNA: Robert SchalkAugust 17, 2023 | forbes.comAncestryDNA vs. 23andMe: Which Is Better?August 11, 2023 | msn.comDNA project collects over 2K samples from offenders, helps solve cold casesAugust 11, 2023 | msn.comCitigroup Maintains 23andMe Holding Co - (ME) Buy RecommendationAugust 10, 2023 | markets.businessinsider.comCiti Keeps Their Hold Rating on 23andMe Holding (ME)August 9, 2023 | finance.yahoo.comWhy 23andMe Holding Stock Plummeted by 13% TodayAugust 9, 2023 | markets.businessinsider.comBerenberg Bank Keeps Their Buy Rating on 23andMe Holding (ME)August 9, 2023 | seekingalpha.com23andMe down 3% on Q1 earnings, guidance revisionSee More Headlines Receive ME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 23andMe and its competitors with MarketBeat's FREE daily newsletter. Email Address ME Company Calendar Last Earnings8/08/2023Today9/26/2023Next Earnings (Estimated)11/06/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ME CUSIPN/A CIK1804591 Webvgacquisition.com Phone650-938-6300FaxN/AEmployees758Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.92 High Stock Price Forecast$7.00 Low Stock Price Forecast$1.75 Forecasted Upside/Downside+382.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-311,660,000.00 Net Margins-110.45% Pretax Margin-111.30% Return on Equity-43.59% Return on Assets-33.26% Debt Debt-to-Equity RatioN/A Current Ratio3.03 Quick Ratio2.93 Sales & Book Value Annual Sales$299.49 million Price / Sales1.61 Cash FlowN/A Price / Cash FlowN/A Book Value$1.55 per share Price / Book0.66Miscellaneous Outstanding Shares472,490,000Free Float342,320,000Market Cap$481.94 million OptionableNot Optionable Beta1.42 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMs. Anne WojcickiCo-Founder, CEO, Pres & Chair of the BoardMr. Joseph Selsavage (Age 60)Interim CFO & Accounting Officer Comp: $574.56kMs. Kathy L. Hibbs Esq. (Age 59)J.D., Chief Admin. Officer & Corp. Sec. Comp: $699.8kDr. Kenneth J. Hillan Ch.B. (Age 62)M.B., Exec. Officer Comp: $711.95kMs. Jacquie Cooke Haggarty J.D.Gen. Counsel & Privacy OfficerMs. Katie Watson (Age 45)VP of Communications Mr. Jonathan WardChief Marketing OfficerMr. Reza Afkhami M.B.A.Chief Corp. Devel. OfficerMs. Savita PillaiVP of PeopleMr. David Baker (Age 52)Chief Security Officer & VP of Engineering More ExecutivesKey CompetitorsCalliditas Therapeutics AB (publ)NASDAQ:CALTEntrada TherapeuticsNASDAQ:TRDATheravance BiopharmaNASDAQ:TBPHAnaptysBioNASDAQ:ANABRepare TherapeuticsNASDAQ:RPTXView All CompetitorsInsiders & InstitutionsKathy L HibbsSold 38,548 sharesTotal: $38,548.00 ($1.00/share)Barclays PLCSold 32,111 shares on 9/21/2023Ownership: 0.021%Kathy L HibbsSold 40,894 sharesTotal: $43,347.64 ($1.06/share)William G RichardsSold 2,538 sharesTotal: $2,741.04 ($1.08/share)Kathy L HibbsSold 40,894 sharesTotal: $42,938.70 ($1.05/share)View All Insider TransactionsView All Institutional Transactions ME Stock - Frequently Asked Questions Should I buy or sell 23andMe stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ME shares. View ME analyst ratings or view top-rated stocks. What is 23andMe's stock price forecast for 2023? 3 Wall Street analysts have issued 12-month target prices for 23andMe's stock. Their ME share price forecasts range from $1.75 to $7.00. On average, they predict the company's share price to reach $4.92 in the next year. This suggests a possible upside of 382.0% from the stock's current price. View analysts price targets for ME or view top-rated stocks among Wall Street analysts. How have ME shares performed in 2023? 23andMe's stock was trading at $2.16 at the beginning of the year. Since then, ME shares have decreased by 52.8% and is now trading at $1.02. View the best growth stocks for 2023 here. When is 23andMe's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our ME earnings forecast. How were 23andMe's earnings last quarter? 23andMe Holding Co. (NASDAQ:ME) announced its earnings results on Tuesday, August, 8th. The company reported ($0.22) earnings per share (EPS) for the quarter. The firm had revenue of $60.86 million for the quarter, compared to analyst estimates of $56.90 million. 23andMe had a negative net margin of 110.45% and a negative trailing twelve-month return on equity of 43.59%. What ETFs hold 23andMe's stock? ETFs with the largest weight of 23andMe (NASDAQ:ME) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON).Global X Telemedicine & Digital Health ETF (EDOC). What guidance has 23andMe issued on next quarter's earnings? 23andMe issued an update on its FY 2024 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $255.00 million-$275.00 million, compared to the consensus revenue estimate of $268.49 million. What is 23andMe's stock symbol? 23andMe trades on the NASDAQ under the ticker symbol "ME." Who are 23andMe's major shareholders? 23andMe's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.19%), State Street Corp (1.34%), Geode Capital Management LLC (1.22%), Renaissance Technologies LLC (0.54%), Northern Trust Corp (0.50%) and Charles Schwab Investment Management Inc. (0.46%). Insiders that own company stock include Kathy L Hibbs, Kenneth J Hillan and William G Richards. View institutional ownership trends. How do I buy shares of 23andMe? Shares of ME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is 23andMe's stock price today? One share of ME stock can currently be purchased for approximately $1.02. How much money does 23andMe make? 23andMe (NASDAQ:ME) has a market capitalization of $481.94 million and generates $299.49 million in revenue each year. The company earns $-311,660,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. How many employees does 23andMe have? The company employs 758 workers across the globe. How can I contact 23andMe? 23andMe's mailing address is 65 BLEECKER STREET 6TH FLOOR, NEW YORK NY, 10012. The official website for the company is vgacquisition.com. The company can be reached via phone at 650-938-6300 or via email at investors@23andme.com. This page (NASDAQ:ME) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 23andMe Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.